<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01641445</url>
  </required_header>
  <id_info>
    <org_study_id>R01AA007850-21</org_study_id>
    <nct_id>NCT01641445</nct_id>
  </id_info>
  <brief_title>Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will help to determine whether the medication, topiramate, reduces alcohol use&#xD;
      among adolescents with alcohol dependence. It will also help answer the question, &quot;How does&#xD;
      topiramate reduce drinking in teenagers?&quot; Understanding how topiramate may reduce drinking in&#xD;
      adolescents would allow for a more targeted pharmacotherapeutic approach to treatment and&#xD;
      help to identify additional medications that may hold promise for improving treatment&#xD;
      outcomes for youth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adolescent alcohol use is associated with myriad adverse legal, health, and educational&#xD;
      consequences and contributes to the leading causes of mortality among youth. Yet despite the&#xD;
      magnitude of this public health problem, treatment initiatives for youth remain inadequate.&#xD;
      Given these data, the National Institute on Alcohol Abuse and Alcoholism identified the&#xD;
      critical need for medications development research for youth with the goal of identifying&#xD;
      promising agents for which large-scale clinical trials are justified. The long-term goal of&#xD;
      this research program is to improve pharmacotherapy for alcoholism. The major objective of&#xD;
      this project is to address the urgent need for empirical data on medications that may benefit&#xD;
      youth. For the past 10 years our research program has successfully paired human laboratory&#xD;
      paradigms with ecological momentary assessment (EMA), whereby research participants use&#xD;
      handheld electronic diaries to monitor their drinking, craving, and sensitivity to alcohol in&#xD;
      real time in their natural environment. Using this approach, we identified mechanisms by&#xD;
      which medications act and patient characteristics that moderate these effects. The proposed&#xD;
      study will test if and how topiramate (TPM), an anticonvulsant shown to be efficacious for&#xD;
      treating adults, reduces drinking in youth. To this end, we will randomize adolescent problem&#xD;
      drinkers to TPM or placebo for 8 weeks, in combination with biweekly motivational enhancement&#xD;
      therapy sessions, using a two-group, double-blind design. While at the target dose (200&#xD;
      mg/day) youth will complete EMA in their natural environment. In addition, youth will&#xD;
      complete alcohol cue reactivity assessments in the laboratory to test the effects of TPM on&#xD;
      cue-elicited craving and physiological reactivity in a controlled environment. Youth will&#xD;
      complete 6- and 12-month follow-up assessments to determine whether any benefits are&#xD;
      sustained. This study will provide much needed data on the tolerability and efficacy of TPM&#xD;
      with adolescents, while adding important new information about the biobehavioral mechanisms&#xD;
      of TPM action in youth.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">April 12, 2017</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol Use</measure>
    <time_frame>Study Weeks 5-8</time_frame>
    <description>Percent drinking days at the target medication dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heavy Drinking Days</measure>
    <time_frame>Study Weeks 5-8</time_frame>
    <description>Percent heavy drinking days at the target medication dose. Heavy drinking is defined as 4 or more standard alcoholic drinks per day for females and 5 or more standard drinks per day for males.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol Use</measure>
    <time_frame>6-month follow-up assessment</time_frame>
    <description>Percent drinking days at the 6-month follow-up assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol Use</measure>
    <time_frame>12-month follow-up assessment</time_frame>
    <description>Percent drinking days at the 12-month follow-up assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Alcohol Drinking</condition>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topiramate (200 mg) taken orally daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (&quot;sugar pill&quot;) taken orally daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Topiramate (200 mg daily)</description>
    <arm_group_label>Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capusules (&quot;sugar pills&quot;</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>&quot;Sugar Pill&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  14-24 years old (inclusive)&#xD;
&#xD;
          -  Non-treatment seeking for alcohol abuse or dependence&#xD;
&#xD;
          -  Interest in reducing alcohol use&#xD;
&#xD;
          -  Self-reported alcohol use at least 2 days/week during prior 28 days&#xD;
&#xD;
          -  Able to read simple English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alcohol or substance abuse treatment in the past 30 days&#xD;
&#xD;
          -  Clinically significant medical abnormalities&#xD;
&#xD;
          -  History of renal impairment, renal stones, or unstable hypertension&#xD;
&#xD;
          -  History of progressive neurodegenerative disorders or clinical significant&#xD;
             neurological disorders&#xD;
&#xD;
          -  Body mass index lower than 18&#xD;
&#xD;
          -  Pregnant, nursing, or refusal to use reliable birth control, if female&#xD;
&#xD;
          -  Non-stabilized psychotropic medication and/or taking medication that is&#xD;
             contraindicated for use with topiramate&#xD;
&#xD;
          -  Medications that may effect alcohol use or a carbonic anhydrase inhibitor&#xD;
&#xD;
          -  Suicidal or psychotic&#xD;
&#xD;
          -  Current coexisting substance use disorders other than alcohol, caffeine, cannabis, or&#xD;
             nicotine use disorders&#xD;
&#xD;
          -  Clinically significant alcohol withdrawal symptoms&#xD;
&#xD;
          -  Impaired cognitive functioning&#xD;
&#xD;
          -  Living with an active study participant&#xD;
&#xD;
          -  Compelled to treatment by the juvenile justice system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Miranda, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brown University, Center for Alcohol and Addiction Studies</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <results_first_submitted>August 28, 2020</results_first_submitted>
  <results_first_submitted_qc>August 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2020</results_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Robert Miranda</investigator_full_name>
    <investigator_title>Associate Professor (Research)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
    <mesh_term>Underage Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT01641445/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Topiramate</title>
          <description>Topiramate (200 mg) taken orally daily</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Placebo (&quot;sugar pill&quot;) taken orally daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topiramate</title>
          <description>Topiramate (200 mg) taken orally daily</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Placebo (&quot;sugar pill&quot;) taken orally daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.88" spread="2.08"/>
                    <measurement group_id="B2" value="20.49" spread="2.05"/>
                    <measurement group_id="B3" value="20.68" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alcohol Use</title>
        <description>Percent drinking days at the target medication dose</description>
        <time_frame>Study Weeks 5-8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate</title>
            <description>Topiramate (200 mg) taken orally daily</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo (&quot;sugar pill&quot;) taken orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Use</title>
          <description>Percent drinking days at the target medication dose</description>
          <units>Percent of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.59" spread="19.55"/>
                    <measurement group_id="O2" value="27.08" spread="21.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Heavy Drinking Days</title>
        <description>Percent heavy drinking days at the target medication dose. Heavy drinking is defined as 4 or more standard alcoholic drinks per day for females and 5 or more standard drinks per day for males.</description>
        <time_frame>Study Weeks 5-8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate</title>
            <description>Topiramate (200 mg) taken orally daily</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo (&quot;sugar pill&quot;) taken orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Heavy Drinking Days</title>
          <description>Percent heavy drinking days at the target medication dose. Heavy drinking is defined as 4 or more standard alcoholic drinks per day for females and 5 or more standard drinks per day for males.</description>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.34" spread="10.99"/>
                    <measurement group_id="O2" value="6.78" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alcohol Use</title>
        <description>Percent drinking days at the 6-month follow-up assessment</description>
        <time_frame>6-month follow-up assessment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate</title>
            <description>Topiramate (200 mg) taken orally daily</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo (&quot;sugar pill&quot;) taken orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Use</title>
          <description>Percent drinking days at the 6-month follow-up assessment</description>
          <units>Percent of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.56" spread="17.11"/>
                    <measurement group_id="O2" value="21.75" spread="21.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alcohol Use</title>
        <description>Percent drinking days at the 12-month follow-up assessment</description>
        <time_frame>12-month follow-up assessment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate</title>
            <description>Topiramate (200 mg) taken orally daily</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo (&quot;sugar pill&quot;) taken orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Use</title>
          <description>Percent drinking days at the 12-month follow-up assessment</description>
          <units>Percent of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.55" spread="22.03"/>
                    <measurement group_id="O2" value="21.93" spread="21.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the 8-week active medication (or placebo pill) period.</time_frame>
      <desc>The definitions of adverse event and serious advserse event are the same as those used by clinicaltrials.gov.</desc>
      <group_list>
        <group group_id="E1">
          <title>Topiramate</title>
          <description>Topiramate (200 mg) taken orally daily</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Placebo (&quot;sugar pill&quot;) taken orally daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Problems</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Changes in Vision</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Slow Thinking or Reactions</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Decrease in Appetite</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Paresthesias</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Runny Nose, Sinus Problems, Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Injuries</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Elevated Heart Rate</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Stomach Discomfort (Cramps/Bloated)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Difficulty with Coordination or Balance</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Drowsiness or Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Difficulty with Memory</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Word Finding Difficulties</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Difficulty with Concentration or Attention</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Miranda</name_or_title>
      <organization>Brown University</organization>
      <phone>401.863.6658</phone>
      <email>Robert_Miranda_Jr@brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

